Polycystic Ovary Syndrome and Obesity: A Cross-Sectional Survey of Patients and Obstetricians/Gynecologists

Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder commonly affecting women of reproductive age. Compared with women without PCOS, women with PCOS are more likely to have overweight or obesity. Materials and Methods: To better understand the role of obstetricians/gynecologists (OB/GYNs) in diagnosis and treatment of patients with PCOS and obesity, we conducted an anonymous, United States population-based, cross-sectional online survey with 251 patients with PCOS and obesity and 305 health care professionals (HCPs), of which 125 were OB/GYNs. Results: In the most common patient journey, most patients were diagnosed (66%) and treated (59%) by OB/GYNs. Most patients (51%) considered OB/GYNs to be the coordinator of their PCOS care. For ongoing management of patients with PCOS and obesity, OB/GYNs reported prescribing general improvements in lifestyle (91%), oral contraceptives (91%), metformin (85%), letrozole (74%), spironolactone (71%), specific diets (60%), medroxyprogesterone (45%), and anti-obesity medications (27%). OB/GYNs were significantly more likely than other HCPs surveyed to strongly agree with the statement that they do not know enough about anti-obesity medications to feel comfortable prescribing them to their patients with PCOS and obesity (p < 0.05). Most OB/GYNs believed that consultation with a dietitian/nutritionist (75%) or access to a physician who specializes in obesity (67%) were the most beneficial types of support for their patients with PCOS and obesity. Conclusions: OB/GYNs recognize the importance of obesity management for the treatment of PCOS; however, utilization of effective obesity tools to treat these patients is low. OB/GYNs may benefit from additional education on obesity management strategies.

[1]  K. Elkind-Hirsch,et al.  Exenatide, dapagliflozin or phentermine/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. , 2021, The Journal of clinical endocrinology and metabolism.

[2]  S. Y. Lee,et al.  Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? , 2021, Current Obesity Reports.

[3]  B. G. Smolarz,et al.  Medicine Residents are Unprepared to Effectively Treat Patients with Obesity: Results from a U.S. Internal Medicine Residency Survey , 2020, Journal of medical education and curricular development.

[4]  D. Dumesic,et al.  Measures of Patient Dissatisfaction With Health Care in Polycystic Ovary Syndrome: Retrospective Analysis , 2020, Journal of medical Internet research.

[5]  R. Kushner,et al.  Low priority of obesity education leads to lack of medical students’ preparedness to effectively treat patients with obesity: results from the U.S. medical school obesity education curriculum benchmark study , 2020, BMC Medical Education.

[6]  L. Williams,et al.  How Effective Are Dietitians in Weight Management? A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2019, Healthcare.

[7]  S. Skinner,et al.  Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding , 2018, Obesity Surgery.

[8]  Carrie D. Patnode,et al.  Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[9]  L. Nazari,et al.  Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome , 2018, JBRA assisted reproduction.

[10]  Madhu Jain,et al.  Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials , 2018, The Journal of Obstetrics and Gynecology of India.

[11]  ACOG Practice Bulletin No. 194 Summary: Polycystic Ovary Syndrome. , 2018, Obstetrics and gynecology.

[12]  Y. Lv,et al.  Comparative efficacy of five long‐term weight loss drugs: quantitative information for medication guidelines , 2017, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  H. Teede,et al.  Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. , 2017, Fertility and sterility.

[14]  J. Pinkney,et al.  The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study , 2017, Journal of advanced nursing.

[15]  Helena Teede,et al.  Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome , 2016, The Journal of clinical endocrinology and metabolism.

[16]  R. Gill,et al.  The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis , 2015, Obesity Surgery.

[17]  S. Arora,et al.  Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates , 2014, Journal of human reproductive sciences.

[18]  Joselyn Rojas,et al.  Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth , 2014, International journal of reproductive medicine.

[19]  L. Moran,et al.  Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. , 2012, Human reproduction update.

[20]  P. Adamshick,et al.  Managing Polycystic Ovary Syndrome , 2011, Journal of holistic nursing : official journal of the American Holistic Nurses' Association.

[21]  T. Wadden,et al.  One‐year Weight Losses in the Look AHEAD Study: Factors Associated With Success , 2009, Obesity.

[22]  I. Katsikis,et al.  Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. , 2008, Fertility and sterility.

[23]  H. Escobar-Morreale,et al.  Abdominal adiposity and the polycystic ovary syndrome , 2007, Trends in Endocrinology & Metabolism.

[24]  M. McCarthy,et al.  Obesity and polycystic ovary syndrome , 2006, Clinical endocrinology.

[25]  S. Atkin,et al.  Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[27]  H. Teede,et al.  Polycystic ovary syndrome , 2016, Nature Reviews Disease Primers.

[28]  L. Moran,et al.  Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. , 2015, Human reproduction update.